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Rationale: Very few patient-reported tools assess health status across different obstructive lung 
diseases. The Chronic Airways Assessment Test (CAAT) is a modification of the chronic obstructive 
pulmonary disease (COPD) Assessment Test (CAT) that is intended to assess health status in patients 
with asthma and/or COPD. With permission, minor modifications were made to the CAT to replace 
the term ‘COPD’ with ‘chronic airways’ and ‘pulmonary disease’ in the questionnaire title and 
instructions, respectively. In all other respects the CAAT is the same as the CAT, including the 
wording of all items, response options, and the scoring. The CAAT score (range: 0–40) is the sum 
score of the 8 items (scored 0–5); higher scores indicate worse health status.  
Methods: The CAAT was evaluated in patients with asthma and/or COPD using cross-sectional 
baseline data from NOVELTY (NCT02760329), a global, prospective, observational study. The total 
sample (N=1,530) for this validation analysis comprised three randomly-selected samples (N=510 
each) from each physician-assigned diagnostic group (asthma, asthma+COPD, COPD). The total 
sample included a subset of patients who also completed the CAT (asthma+COPD: n=37; COPD: 
n=46). Psychometric analyses included descriptive statistics, tests of validity and reliability, and 
differential item functioning via Item Response Theory (IRT). 
Results: CAAT items were internally consistent in each diagnostic group (Cronbach’s alphas ranged 
from 0.84 to 0.87; Table), a prerequisite for use as a single-factor tool in patients with asthma and/or 
COPD. Tests for convergent and divergent validity coefficients between the CAAT and clinical 
assessments found strong convergent correlations (>0.7) with health status assessed by the St. 
George’s Respiratory Questionnaire, and divergent (i.e. weak) correlations with some spirometry 
measures (Table). CAAT scores also differed significantly between clinically identifiable groups 
(physician-assigned diagnosis and physician-assessed severity groups, mMRC dyspnea scale grades, 
exacerbation history, and, in patients with an asthma diagnosis, Asthma Control Test scores). 
Furthermore, IRT analysis suggests that items had a good overall fit; item response boundary 
 
 
locations were monotonic and in the expected order. Models of measurement and structural 
invariance were strong. 
Conclusions: Overall, this analysis demonstrates that the CAAT is a valid patient-reported tool with 
established cross-sectional psychometric properties. It correlated well with health status measures 
in NOVELTY patients with diagnoses of asthma and/or COPD. The CAAT is a suitable diagnosis-
agnostic patient-reported tool for use in obstructive lung disease, and because of its brevity, may be 
particularly relevant for real-world clinical studies and routine clinical practice where time is limited. 
 
 










Demographic and clinical characteristics     
Age, mean years (SD) 54.6 (15.7) 65.2 (9.9) 67.3 (9.6) 62.4 (13.3) 
Female, n (%) 328 (64.3) 240 (47.1) 203 (39.8) 771 (50.4) 
CAAT score, mean (SD) 13.7 (8.2) 17.2 (8.6) 16.9 (8.2) 15.9 (8.5) 
Internal consistency      
Cronbach’s alphas for each diagnosis group 0.87 
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The CAAT is a trademark of the GlaxoSmithKline group of companies. © 2009 GlaxoSmithKline. All rights reserved. It has been 
modified from the CAT, with permission, by replacement of the term ‘COPD’ with ‘chronic airways’ and ‘pulmonary disease’ in the 
questionnaire title and instruction, respectively.  
a
Correlation coefficients (Pearson’s r) >0.70 are regarded as strong; 0.4–0.7 as moderate; and <0.4 as weak. 
CAAT, Chronic Airways Assessment Test; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; EQ VAS, 
EuroQol Visual Analog Scale; FEF, forced expiratory flow; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 
mMRC, modified Medical Research Council; N, total number of patients in the sample; n, number of patients with non-missing 
data; NA, not applicable; RSQ, Respiratory Symptoms Questionnaire; SD, standard deviation; SGRQ, St. George’s Respiratory 
Questionnaire. 
*p<0.05; **p<0.001; ***p<0.0001. 
 
 
